Anti-tuberculosis (TB) drug resistance is a major public health problem that threatens TB treatment progress made
in the inhabitants of countries in Europe, Asia, Africa, and the America. A retrospective study for the pulmonary TB
cases admitted to Quefia Chest Hospital Benghazi, Libya, from 1/1/2009 till 1/6/2010 showed that 4 cases out of
430 TB patients were positive for sensitivity culture and didn\'t respond to the first line anti-TB therapy and therefore
were diagnosed as Multidrug Resistant Tuberculosis (MDR-TB). One of these patients was Libyan while others
were aliens. The 2nd line anti-TB drugs were given in the form of Amikacin injection, cycloserine, moxifloxacin and
pyrazinamide for the first 6 months followed by 18 months therapy with moxifloxacin, cycloserine and
pyrazinamide. Follow-up with the patients exhibited clinical-radiological and microbiological improvement.